Innate Pharma FY2025 EPS Forecast Increased by HC Wainwright

Innate Pharma S.A. Sponsored ADR (NASDAQ:IPHA) – Stock analysts at HC Wainwright upped their FY2025 earnings estimates for shares of Innate Pharma in a research note issued to investors on Wednesday, October 29th. HC Wainwright analyst S. Ramakanth now expects that the company will post earnings per share of ($0.65) for the year, up from their prior estimate of ($0.66). HC Wainwright has a “Strong-Buy” rating on the stock. HC Wainwright also issued estimates for Innate Pharma’s FY2026 earnings at ($0.64) EPS, FY2027 earnings at ($0.48) EPS, FY2028 earnings at ($0.15) EPS and FY2029 earnings at $0.13 EPS.

IPHA has been the topic of a number of other research reports. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Innate Pharma in a research report on Wednesday, October 8th. BTIG Research reaffirmed a “buy” rating and issued a $8.00 price objective on shares of Innate Pharma in a research report on Wednesday. Leerink Partnrs downgraded shares of Innate Pharma from a “strong-buy” rating to a “hold” rating in a research report on Thursday, September 18th. Finally, Leerink Partners reaffirmed a “market perform” rating and issued a $2.00 price objective (down previously from $10.00) on shares of Innate Pharma in a research report on Thursday, September 18th. One equities research analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Innate Pharma presently has an average rating of “Hold” and an average target price of $5.00.

Innate Pharma Price Performance

NASDAQ IPHA opened at $1.97 on Friday. The company’s 50-day simple moving average is $2.03 and its two-hundred day simple moving average is $2.04. Innate Pharma has a one year low of $1.29 and a one year high of $3.51.

Innate Pharma Company Profile

Innate Pharma SA, a biotechnology company, develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH6401, an BCMA-targeting NK cell engager; and IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager.